Vancomycin, a gram-positive bactericidal agent, represents the drug of choice for infections caused by methicilin-resistant Staphylococcus aureus, common microorganisms implicated in infections and systemic sepsis in burned patients. Even though the toxicity of the current method of preparation of vancomycin has been reduced by an improved purification method [1] , the concentration of vancomycin in the blood should be monitored closely in burned patients to maintain adequate anti-infective concentrations in patients with particularly high total body clearance and volume of distribution. This monitoring can be performed by determining the peak and trough serum concentrations of vancomycin. For this purpose, different analytical techniques are available, mainly immunoassays such as the fluorescence polarization immunoassay (FPIA) developed by Abbott Diagnostic Laboratories (Chicago, IL) [2] on the TDx analyzer and the enzyme-multiplied immunotechnique assay (Emit) developed by Syva-Behring Laboratories (San Jose, CA). FPIA is a fast, reliable, and automated technique frequently used in large laboratories. However, in a few selected situations some interferences may occur. One possible interference has been reported to be due to accumulating vancomycin degradation products in renal failure [3, 4] , which could result in overestimated concentrations. However, a recent study conducted in patients with renal dysfunction did not report any substantial differences in the vancomycin concentrations obtained by FPIA and Emit during the first week after the onset of the treatment [5] .
Recently, we have been able to detect another origin of interference in the FPIA vancomycin assay. Some serum specimens displayed unusually high blank values (Ͼ100fold increase) as compared with routine blank data in the vancomycin FPIA. All of these serum specimens originated from burned patients treated simultaneously with intravenous (i.v.) vancomycin and topical eosin. Indeed, a rational approach in the treatment of burn injuries involves topical wound therapy as an adjunct to systemic antibiotics. Eosin, a topical chemotherapeutic agent, is used frequently on severely burned patients, in baths with an aqueous solution of eosin (20 g/L) up to 6 times/day for disinfection of skin and wounds. Eosin, also called bromofluorescein, is prepared from bromination of fluorescein. Because fluorescein is used in FPIA technology as a tracer, we highly suspected eosin as the origin of the interference observed. To assess the potential role played by eosin in the FPIA interference, we supplemented vancomycin-free human serum with different vancomycin concentrations resulting in final theoretical concentrations of 0, 4.9, 24.5, and 52.5 mg/L. To these solutions we added different amounts of eosin diluted in the FPIA buffer, resulting in final eosin concentrations of 0, 1.9, 3.8, 7.5, 12, 15, and 30 mg/L. Each solution was assayed five times on the TDx analyzer.
Eosin added to vancomycin-free serum samples caused important background interferences. Mean blank intensity data increased linearly (1619, 3074, 5942, 8009, 12 562, and 19 317 arbitrary units, respectively) with the eosin concentration, resulting in a dramatic decrease of the vancomycin concentration detected (Fig. 1 ). This negative interference ranged from 13% to 58% according to the eosin concentration and appeared to be statistically significant (P Ͻ0.05) or even highly significant (P Ͻ0.0005) for low eosin concentrations (1.9 and 3.8 mg/L) or high concentrations (30 mg/L), respectively (Student's t-test for comparison of two means).
To minimize eosin interference in the vancomycin FPIA we used an ultrafiltration method (disposable Amicon Centrifree ® devices) to separate eosin and protein-bound vancomycin from free vancomycin. Small volumes (0.5-0.8 mL) of patient serum were used with these devices, centrifuged at 2000g for 30 min, finally resulting in a clear and colorless ultrafiltrate taken for further vancomycin measurements. A first control group of 45 serum samples from nonburned patients without eosin but treated with The estimated eosin concentration is obtained with the equation: y ϭ 0.0014x, where x is the blank intensity value with eosin interference. All data have been determined 5 times, and the mean Ϯ SD are shown. vancomycin (i.v.) were tested to evaluate the recovery of vancomycin after ultrafiltration. Total vancomycin concentrations measured on these samples before ultrafiltration ranged from 2.5 to 39.7 mg/L, with normal blank data presenting a mean value (ϮSE) of 149 Ϯ 70 mg/L (range: 55 to 320). Vancomycin concentrations (free fraction) measured after ultrafiltration were 10% to 33% lower than the concentrations measured without ultrafiltration. Blank values of ultrafiltrate were not substantially different from those before ultrafiltration. A linear regression between the results obtained before (y) and after (x) ultrafiltration is described by the following equation:
A second group of 18 serum specimen obtained from burned patients under vancomycin (i.v) and topical eosin treatment was processed the same way. In this group blank data during FPIA vancomycin determination displayed a mean value (ϮSE) of 11 520 Ϯ 5643 (range: 4522 to 20 388). Blank values obtained subsequently in the ultrafiltrate were homogeneously lower and reached a mean (ϮSE) of 128 Ϯ 14 (range: 108 to 172), similar to the control group. Free vancomycin concentrations found in these patients ranged from 5.9 to 22 mg/L. Total vancomycin circulating concentrations in this group of patients should be corrected by taking into account the recovery by application of Eq. 1. Estimated total vancomycin concentrations ranged from 8 to 33 mg/L.
Total circulating vancomycin concentrations in that group of patients could also be obtained by another approach. In the absence of ultrafiltration Centrifree devices, the eosin concentration in patient serum could be estimated from the blank value. Indeed, the correlation between serum eosin concentration (y) and blank values (x) obtained during vancomycin measurements is described by the equation:
Once the eosin concentration is estimated, the second step consists of using Fig. 1 to estimate the corrected vancomycin concentration from the observed and underestimated vancomycin concentration. Results obtained by the two approaches are similar (Student's t-test for comparison of two means, P ϭ 0.13). Ideally, a topical agent in burn therapy should penetrate the wound, yet not be appreciably absorbed systemically. Nevertheless, it is well known that burn wounds do have a potentially absorptive surface. Some previously popular topical agents used on burns were abandoned after it was recognized that substantial absorption and, as a result, prohibitive systemic toxicity resulted from their use [6] .
We have demonstrated that eosin cutaneously absorbed in burn wounds during eosin baths presents an important interference in the FPIA vancomycin analysis. The clinical impact of such interference is not negligible because it could result in overdosage of this antibiotic onthe basis of falsely low concentrations, with subsequent increased risk of toxicity. To our knowledge, no data are available on eosin pharmacokinetics indicating how rapidly eosin is cleared from the body. In our experience, however, such interference may take days to disappear after interruption of eosin application. Even though we know that eosin is structurally related to fluorescein and causes an important background, the origin for such interference is still unclear. The influence of an increased background or some protein binding of eosin is not sufficient to explain the underestimation, because other drug assays are not affected the same way.
Our work has focused on potentially toxic antibiotic interferences because burned patients represent a population particularly affected by nosocomial infections. Other antibiotics such as aminoglycosides monitored in burned patients have been tested with eosin as well, resulting in increased blank intensity data, but without any detectable analytical interference in the concentrations found. Among 23 different drugs tested, usually followed in therapeutic drug monitoring, only tricyclic antidepressants, phenobarbital, and acetaminophen presented some negative interference with eosin, whereas theophylline showed even a positive interference with increased drug concentrations in the presence of eosin. The interference observed in the vancomycin assay could result from a possible eosin interaction directly with the drug. The percentage of vancomycin loss in the ultrafiltrate could reflect the degree of vancomycin binding to plasma proteins. In fact, recent observations in patients with normal renal function suggest that approximately one-third of the circulating vancomycin is bound, mainly to albumin [7] . The degree of binding in patients with end-stage renal disease is somewhat lower (mean 18.5%, range 0% to 30.6%) [8] , therefore affecting Eq. 1 to have a slope value Ͻ1.55.
In conclusion, the ultrafiltration procedure represents a first-choice method to minimize eosin interference in the vancomycin FPIA, because it completely removes eosin from the serum. In the absence of this procedure, corrected concentrations could still be obtained by evaluating the eosin concentration with Eq. 2, then using Fig. 1 as described above. These two approaches should allow each laboratory to face this particular situation. Centers accustomed to the monitoring of free drug concentrations might prefer to report only free fractions of vancomycin instead of estimating a total vancomycin concentration.
